Redhill Biopharma Ltd. (NASDAQ:RDHL – Get Free Report) was the target of a large decline in short interest during the month of October. As of October 30th, there was short interest totaling 61,151 shares, a decline of 52.3% from the October 15th total of 128,328 shares. Approximately 0.7% of the shares of the company are short sold. Based on an average trading volume of 132,590 shares, the days-to-cover ratio is presently 0.5 days.
Analysts Set New Price Targets
Separately, Weiss Ratings downgraded shares of Redhill Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, October 6th. One analyst has rated the stock with a Sell rating. According to data from MarketBeat, the company has an average rating of “Sell”.
View Our Latest Stock Report on RDHL
Redhill Biopharma Trading Down 0.4%
Shares of RDHL stock traded down $0.00 during trading on Tuesday, hitting $0.36. The company had a trading volume of 40,979 shares, compared to its average volume of 799,505. Redhill Biopharma has a one year low of $0.34 and a one year high of $1.60. The stock’s 50-day moving average price is $0.49 and its 200 day moving average price is $0.76.
About Redhill Biopharma
RedHill Biopharma is a biopharmaceutical company founded in 2009 and based in Israel, with a focus on developing and commercializing treatments for gastrointestinal and infectious diseases. Its activities have included drug development, regulatory and clinical research, and product commercialization, particularly in the United States. The company’s product portfolio has included Talicia, a combination therapy approved in the United States for adults with Helicobacter pylori infection, and Aemcolo, an antibiotic approved for certain cases of travelers’ diarrhea.
Recommended Stories
- Five stocks we like better than Redhill Biopharma
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Redhill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redhill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
